Compare NetApp Inc. (NTAP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Sana Biotechnology Inc — how do they compare? NetApp Inc. trades at $167 (market cap $31.57B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: NetApp Inc. is far larger — about 36.1× Sana Biotechnology Inc's market cap, and NetApp Inc. pays a 1.29% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NTAP | SANA | |
|---|---|---|
Market Cap | $31.57B | $873.84M |
Sector | Technology | Health |
52-Week High | $181.08 | $5.92 |
52-Week Low | $94.11 | $2.68 |
Enterprise Value | $30.72B | $848.03M |
Dividend Yield | 1.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTAP trades at $165.70, up 1.11% today, near its consensus price target of $167.45. The stock shows strong fundamentals with a net income margin of 18.43% and consistent earnings beats in recent quarters. Recent acquisition of DataPelago aims to bolster AI infrastructure capabilities, while technical indicators signal a neutral near-term trend with support at $160 and resistance at $166.
Outlook remains positive driven by AI and cloud demand, though high valuation ratios like P/E of 25.38 and debt-to-asset ratio of 29.89 pose risks. Analysts are mixed with 36.6% buy ratings, suggesting cautious optimism for growth trajectory amid competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
